收益表 (TTM)
Alivus 生命科学有限公司 损益表显示一段时间内收入和支出的变化。损益表数据包括销售和收入、毛利、研发、销售、一般和管理费用、经营收入、所得税费用、利息费用、营业外收入、每股收益和已发行股票。
除每股单位外,所有数字都是 1,000,000。
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
收入 | 18,852 | 20,131 | 20,540 | 20,763 | 21,232 | 20,882 | 20,357 | 20,540 | 21,612 | 22,498 | 23,359 | 23,679 | 22,832 | 22,934 | 22,049 | 22,739 | 23,869 | 24,001 |
改变 (%) | 6.79 | 2.03 | 1.08 | 2.26 | -1.65 | -2.51 | 0.90 | 5.22 | 4.10 | 3.83 | 1.37 | -3.58 | 0.45 | -3.86 | 3.13 | 4.97 | 0.55 | |
收入百分比 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
销售成本 | 9,342 | 10,182 | 9,954 | 10,090 | 10,677 | 10,124 | 10,060 | 10,136 | 10,468 | 10,332 | 10,991 | 10,765 | 10,399 | 10,418 | 10,318 | 10,749 | 11,308 | 10,634 |
改变 (%) | 8.98 | -2.24 | 1.36 | 5.82 | -5.18 | -0.64 | 0.76 | 3.28 | -1.30 | 6.37 | -2.06 | -3.39 | 0.18 | -0.96 | 4.18 | 5.20 | -5.95 | |
收入百分比 | 49.56 | 50.58 | 48.46 | 48.59 | 50.29 | 48.48 | 49.42 | 49.35 | 48.44 | 45.93 | 47.05 | 45.46 | 45.55 | 45.42 | 46.79 | 47.27 | 47.37 | 44.31 |
毛营业利润 | 9,509 | 9,949 | 10,586 | 10,673 | 10,555 | 10,758 | 10,298 | 10,403 | 11,144 | 12,166 | 12,368 | 12,915 | 12,433 | 12,516 | 11,731 | 11,991 | 12,561 | 13,367 |
改变 (%) | 4.63 | 6.40 | 0.82 | -1.11 | 1.92 | -4.28 | 1.03 | 7.12 | 9.17 | 1.66 | 4.42 | -3.73 | 0.67 | -6.27 | 2.21 | 4.76 | 6.41 | |
收入百分比 | 50.44 | 49.42 | 51.54 | 51.41 | 49.71 | 51.52 | 50.58 | 50.65 | 51.56 | 54.07 | 52.95 | 54.54 | 54.45 | 54.58 | 53.21 | 52.73 | 52.63 | 55.69 |
销售、一般及行政费用 | 1,553 | 1,608 | 1,669 | 1,733 | 1,744 | 1,722 | 1,768 | 1,812 | 1,896 | 1,879 | 2,166 | 2,391 | 2,701 | 2,669 | 2,745 | 2,692 | 2,705 | 2,564 |
改变 (%) | 3.49 | 3.78 | 3.89 | 0.63 | -1.26 | 2.62 | 2.49 | 4.66 | -0.93 | 15.32 | 10.39 | 12.94 | -1.19 | 2.87 | -1.95 | 0.51 | -5.22 | |
收入百分比 | 8.24 | 7.99 | 8.12 | 8.35 | 8.22 | 8.25 | 8.68 | 8.82 | 8.77 | 8.35 | 9.27 | 10.10 | 11.83 | 11.64 | 12.45 | 11.84 | 11.33 | 10.68 |
研发 | ||||||||||||||||||
改变 (%) | ||||||||||||||||||
收入百分比 | ||||||||||||||||||
运营支出 | 13,234 | 14,294 | 14,329 | 14,653 | 15,443 | 15,246 | 14,954 | 15,153 | 15,605 | 16,059 | 16,712 | 16,786 | 16,611 | 17,080 | 16,529 | 17,062 | 17,631 | 17,680 |
改变 (%) | 8.00 | 0.24 | 2.26 | 5.39 | -1.27 | -1.92 | 1.33 | 2.98 | 2.91 | 4.06 | 0.44 | -1.04 | 2.83 | -3.23 | 3.22 | 3.34 | 0.28 | |
收入百分比 | 70.20 | 71.00 | 69.76 | 70.57 | 72.73 | 73.01 | 73.46 | 73.77 | 72.20 | 71.38 | 71.55 | 70.89 | 72.75 | 74.48 | 74.97 | 75.03 | 73.87 | 73.66 |
营业收入 | 5,617 | 5,837 | 6,212 | 6,110 | 5,789 | 5,635 | 5,403 | 5,387 | 6,008 | 6,439 | 6,647 | 6,894 | 6,221 | 5,853 | 5,520 | 5,678 | 6,238 | 6,321 |
改变 (%) | 3.91 | 6.42 | -1.63 | -5.25 | -2.66 | -4.12 | -0.30 | 11.52 | 7.17 | 3.23 | 3.71 | -9.75 | -5.91 | -5.70 | 2.86 | 9.87 | 1.34 | |
收入百分比 | 29.80 | 29.00 | 30.24 | 29.43 | 27.27 | 26.99 | 26.54 | 26.23 | 27.80 | 28.62 | 28.45 | 29.11 | 27.25 | 25.52 | 25.03 | 24.97 | 26.13 | 26.34 |
利息花费 | -875 | -853 | -706 | -490 | -280 | -75 | -5 | -6 | -5 | -8 | -11 | -13 | -15 | -15 | -14 | -15 | -24 | -33 |
改变 (%) | -2.59 | -17.21 | -30.58 | -42.95 | -73.01 | -93.98 | 21.81 | -1.08 | 47.71 | 32.92 | 21.14 | 18.83 | -2.78 | -3.73 | 4.91 | 59.03 | 37.20 | |
收入百分比 | -4.64 | -4.24 | -3.44 | -2.36 | -1.32 | -0.36 | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 | -0.05 | -0.07 | -0.07 | -0.07 | -0.07 | -0.10 | -0.14 |
净利 | 3,516 | 3,714 | 4,142 | 4,245 | 4,187 | 4,265 | 4,182 | 4,195 | 4,670 | 4,937 | 5,055 | 5,193 | 4,709 | 4,469 | 4,235 | 4,417 | 4,856 | 4,957 |
改变 (%) | 5.65 | 11.50 | 2.50 | -1.36 | 1.87 | -1.95 | 0.31 | 11.31 | 5.72 | 2.40 | 2.72 | -9.32 | -5.09 | -5.24 | 4.30 | 9.95 | 2.07 | |
收入百分比 | 18.65 | 18.45 | 20.16 | 20.45 | 19.72 | 20.43 | 20.54 | 20.42 | 21.61 | 21.94 | 21.64 | 21.93 | 20.62 | 19.49 | 19.21 | 19.42 | 20.35 | 20.65 |
Source: Capital IQ